Investors might want to bet on Alpha Teknova (TKNO) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The pow ...

财务数据和关键指标变化 - 第一季度总收入为9.3百万美元,较上年同期增长2% [28][29][30][31] - 实验室基础产品收入为7.3百万美元,与上年同期持平 [29] - 临床解决方案收入为1.7百万美元,较上年同期增长7% [30][31][32] - 毛利润为2.2百万美元,毛利率为23.8%,较上年同期下降2.8个百分点 [34][35] - 经调整EBITDA为负3.8百万美元,较上年同期改善2.3百万美元 [38] - 自由现金流为负6.7百万美元,较上年同期改善5.3百万美元 [40][41] 各条业务线数据和关键指标变化 - 实验室基础产品客户数略有增加,但平均收入有所下降 [29] - 临床解决方案客户数有所增加,但平均收入有所下降 [31][32] - 临床解决方案业务收入波动较大,需要观察几个季度才能确定趋势 [33] 各个市场数据和关键指标变化 - 公司没有单一客户占比超过10%的情况,客户集中度较低 [14] - 临床解决方案客户数持续增加,为长期发展提供积极信号 [14] 公司战略和发展方向及行业竞争 - 公司推出新产品AAV-Tek AAV Stabilizer和Build-Tek定制配置器,提升产品竞争力 [19][20] - 公司认为行业融资环境正在好转,预计2025年初市场环境将更加乐观 [22][23] - 公司正在积极执行成本控制措施,预计2024年全年现金流出将低于18百万美元 [45][46] 管理层对经营环境和未来前景的评论 - 管理层认为公司在2024年开局良好,对长期发展前景保持乐观 [48] - 管理层表示正在执行成本控制措施,并将继续保持关键投资,以实现长期增长目标 [43][44] 问答环节重要的提问和回答 问题1 **Jacob Johnson 提问** 临床解决方案业务在本季度表现强劲,是否可以视为全年趋势 [51][52][53] **Stephen Gunstream 回答** 临床解决方案业务收入波动较大,需要观察几个季度才能确定趋势 [52][53] 问题2 **Steven Mah 提问** Build-Tek定制配置器的市场需求情况如何 [58][59][60][61] **Stephen Gunstream 回答** 这是一个新推出的创新产品,目前还处于早期阶段,但客户反响良好,公司看好这一市场的发展前景 [59][60][61] 问题3 **Matt Larew 提问** 公司的资本支出情况及未来投资计划 [72][73][74][75] **Matthew Lowell 回答** 公司将维持较低的资本支出水平,未来可能会有一些必要的维护性投入和支持新业务发展的投资 [74][75]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40538 ALPHA TEKNOVA, INC. (Exact name of registrant as specified in its charter) Delaware 94-3368109 (State or other jurisdiction ...

Exhibit 99.1 Teknova Reports First Quarter 2024 Financial Results First quarter 2024 total revenue was $9.3 million, up 2% from prior year Launch of Build-TekTM Custom Configurator Company reaffirms 2024 revenue guidance of $35-38 million HOLLISTER, Calif., May 13, 2024 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced financi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40538 ALPHA TEKNOVA, INC. (Exact name of registrant as specified in its charter) Delaware 94-3368109 (State or other jurisdiction of ...

Alpha Teknova, Inc. (NASDAQ:TKNO) Q4 2023 Earnings Conference Call March 11, 2024 5:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Jacob Johnson - Stephens Steven Mah - TD Cohen Madeline Mollman - William Blair Paul Knight - KeyBanc Operator Hello, and thank you for standing by. Welcome to Teknova Fourth Quarter 2023 Financial Re ...

Exhibit 99.1 Teknova Reports Fourth Quarter and Full Year 2023 Financial Results Full year 2023 total revenue was $36.7 million, down 11% year-over-year Achieved 36% annual growth in the number of Clinical Solutions customers in 2023 Company provides 2024 revenue guidance of $35-38 million HOLLISTER, Calif., March 11, 2024 – Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a leading producer of critical reagents for the discovery, development, and commercialization of novel therapies, vaccin ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40538 ALPHA TEKNOVA, INC. (Exact name of registrant as specified in its charter) Delaware 94-3368109 (State or other jurisdic ...

Alpha Teknova, Inc. (NASDAQ:TKNO) Q3 2023 Earnings Conference Call November 9, 2023 5:30 PM ET Company Participants Jennifer Henry - Senior Vice President of Marketing Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Jacob Johnson - Stephens Steven Mah - TD Cohen Matt Larew - William Blair Anna Snookowski - KeyBanc Mark Massaro - BTIG Operator Hello, and welcome to Alpha Tech Nova, Inc. Third Quarter 2023 Financial Results Conferen ...

Alpha Teknova, Inc. (NASDAQ:TKNO) Q2 2023 Earnings Conference Call August 10, 2023 5:30 PM ET Company Participants Sara Michelmore - MacDougall Advisors Stephen Gunstream - President & Chief Executive Officer Matthew Lowell - Chief Financial Officer Conference Call Participants Steven Mah - TD Cowen Matt Larew - William. Blair Paul Knight - KeyBanc Mark Massaro - BTIG Jacob Johnson - Stephens Operator Good day, and welcome to Teknova’s Second Quarter 2023 Financial Results Conference Call. At this time, all ...